

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1 Revision Date: 2025/04/14 SDS Number: 809027-00023 Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Bezlotoxumab Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.  
Menuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

**GHS classification of chemical product**

Not a hazardous substance or mixture according to the Globally Harmonised System (GHS).

**GHS label elements**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards which do not result in classification**

None known.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Bezlotoxumab	1246264-45-8	>= 1 - < 10	-

---

### 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

---

Version 6.1	Revision Date: 2025/04/14	SDS Number: 809027-00023	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

---

In case of skin contact	: Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: None known.
Protection of first-aiders	: No special precautions are necessary for first aid responders.
Notes to physician	: Treat symptomatically and supportively.

---

## 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1	Revision Date: 2025/04/14	SDS Number: 809027-00023	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

cannot be contained.

Methods and materials for containment and cleaning up

- : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

## 7. HANDLING AND STORAGE

### Handling

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : Use only with adequate ventilation.

Advice on safe handling

- : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact

- : Oxidizing agents

Hygiene measures

- : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### Storage

Conditions for safe storage

- : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid

- : Do not store with the following product types:

Strong oxidizing agents

Packaging material

- : Unsuitable material: None known.

---

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Threshold limit value and permissible exposure limits for each component in the work environment**

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1 Revision Date: 2025/04/14 SDS Number: 809027-00023 Date of last issue: 2024/09/28 Date of first issue: 2016/07/22

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Bezlotoxumab	1246264-45-8	TWA	5.0 mg/m <sup>3</sup> (OEB 1)	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : Aqueous solution

Colour : Colorless to pale yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1      Revision Date: 2025/04/14      SDS Number: 809027-00023      Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

Upper explosion limit / Up- per flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Decomposition temperature	: No data available
pH	: 5.7 - 6.3
Evaporation rate	: No data available
Auto-ignition temperature	: No data available
Viscosity	
Viscosity, dynamic	: 1.2 mPa.s (25 °C)
Viscosity, kinematic	: 1.833 mm <sup>2</sup> /s (4 °C)
	1.183 mm <sup>2</sup> /s (25 °C)
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n- octanol/water	: Not applicable
Vapour pressure	: No data available
Density and / or relative density	
Relative density	: No data available
Density	: 1.0146 g/cm <sup>3</sup>
Relative vapour density	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

---

## 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1      Revision Date: 2025/04/14      SDS Number: 809027-00023      Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **Bezlotoxumab:**

Acute toxicity (other routes of administration) : LD50 (Mouse): > 125 mg/kg  
Application Route: Intravenous  
Remarks: No adverse effect has been observed in acute toxicity tests.

#### **Skin corrosion/irritation**

Not classified based on available information.

#### **Serious eye damage/eye irritation**

Not classified based on available information.

#### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### **Germ cell mutagenicity**

Not classified based on available information.

#### **Carcinogenicity**

Not classified based on available information.

#### **Reproductive toxicity**

Not classified based on available information.

#### **STOT - single exposure**

Not classified based on available information.

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version  
6.1

Revision Date:  
2025/04/14

SDS Number:  
809027-00023

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### **Bezlotoxumab:**

Species	:	Mouse
NOAEL	:	50 mg/kg
Application Route	:	Intravenous
Exposure time	:	15 d
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	125 mg/kg
Application Route	:	Intravenous
Exposure time	:	21 d
Remarks	:	No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### **Bezlotoxumab:**

Inhalation	:	Symptoms: Nausea, Headache, Diarrhoea, Fever
------------	---	--

---

## 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

No data available

### **Persistence and degradability**

No data available

### **Bioaccumulative potential**

No data available

### **Mobility in soil**

No data available

### **Hazardous to the ozone layer**

Not applicable

### **Other adverse effects**

No data available

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version 6.1      Revision Date: 2025/04/14      SDS Number: 809027-00023      Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Environmentally hazardous : no

##### IATA-DGR

UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

##### IMDG-Code

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

Refer to section 15 for specific national regulation.

#### Special precautions for user

Not applicable

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

---

Version 6.1	Revision Date: 2025/04/14	SDS Number: 809027-00023	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

---

## 15. REGULATORY INFORMATION

### Related Regulations

#### Fire Service Law

Not applicable to dangerous materials / designated flammables.

#### Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

#### Industrial Safety and Health Law

##### Harmful Substances Prohibited from Manufacture

Not applicable

##### Harmful Substances Required Permission for Manufacture

Not applicable

##### Substances Prevented From Impairment of Health

Not applicable

##### Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

##### Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

##### Substances Subject to be Notified Names

Not applicable

##### Substances Subject to be Indicated Names

Not applicable

##### Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

##### Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

##### Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

##### Ordinance on Prevention of Lead Poisoning

Not applicable

##### Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

##### Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

---

Version 6.1	Revision Date: 2025/04/14	SDS Number: 809027-00023	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

---

### **Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

### **Poisonous and Deleterious Substances Control Law**

Not applicable

### **Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

### **High Pressure Gas Safety Act**

Not applicable

### **Explosive Control Law**

Not applicable

### **Vessel Safety Law**

Not regulated as a dangerous good

### **Aviation Law**

Not regulated as a dangerous good

### **Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

### **Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

### **Waste Disposal and Public Cleansing Law**

Industrial waste

### **The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

## 16. OTHER INFORMATION

### **Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

# SAFETY DATA SHEET



## Bezlotoxumab Formulation

Version  
6.1

Revision Date:  
2025/04/14

SDS Number:  
809027-00023

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN